The MTHFD2 protein is uniquely expressed in cancer and not in normal tissue. Yet, it is required for survival in cancer, but not for normal cells. This makes it a highly interesting target, with the potential of finding compounds that selectively kill cancer cells, but not normal cells. Key to success is to determine the crystal structure of the MTHFD2. We are really happy to present, in a report published in Cancer Research on Febuary 15, that we have resolved the MTHFD2 crystal structure together with a small molecule inhibitor of MTHFD2. This makes our way to finding really potent inhibitors much easier.
- Medicinal Chemistry Projects available at The Helleday Laboratories Stockholm
- Nicholas Valerie awarded with “Dan Grandér Memorial Prize” for best cancer related PhD thesis at KI
- Sean Rudd receives Grants from VR and Karolinska to start own independent research
- Helleday lab on track to novel potent OGG1 inhibitors beyond TH5487
- Biberach students visit the labs